We're doing drug trials wrong – here's how to fix it
By the age of 65, at least half of us will suffer from two or more long-term diseases. And the chance of having multi-morbidity, as it is known, increases with age.
Oct 18, 2018
0
0
By the age of 65, at least half of us will suffer from two or more long-term diseases. And the chance of having multi-morbidity, as it is known, increases with age.
Oct 18, 2018
0
0
A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to ...
Oct 12, 2018
0
109
A new clinical trial at Emory University and 45 other sites around the U.S. will test a combination of vitamins and steroids in patients diagnosed with sepsis. Sepsis is caused by the body's overwhelming and life-threatening ...
Oct 11, 2018
1
1
With more than 35 million people worldwide living with the virus and nearly 2 million new cases each year, the human immunodeficiency virus (HIV) remains a major global epidemic. Existing antiretroviral drugs do not cure ...
Oct 3, 2018
0
93
Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers in the body, threatening to rise to dangerous levels ...
Sep 26, 2018
0
95
A translational research team led by the National University of Singapore (NUS) has harnessed CURATE.AI, a powerful artificial intelligence (AI) platform, to treat a patient with advanced cancer, completely halting disease ...
Sep 4, 2018
0
6
Immune activation and inflammation persist in the majority of treated HIV-infected individuals and is associated with excess risk of mortality and morbidity. A new study by Boston University School of Medicine (BUSM) researchers ...
Aug 27, 2018
0
10
A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence (AI) technology platform that could potentially change the way drug combinations are being designed, ...
Aug 13, 2018
0
2
Bacteria—especially Gram-negative strains—are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed. Faced with these challenges, investigators are studying ...
Aug 10, 2018
0
3
New-generation lung cancer drugs have been effective in a large number of patients, but within about a year, the patients tend to develop resistance to the therapy. Researchers at the Weizmann Institute of Science, in collaboration ...
Jul 25, 2018
0
4